BMS 246 - Systemic Lupus Erythematosus (SLE)
- Study HIC#:2000033879
- Last Updated:04/02/2024
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
Contact Us
For more information about this study, including how to volunteer, contact:
Lupus Research
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Trial Purpose and Description
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
Eligibility Criteria
The target population is SLE subjects between the ages of 18 and 75 with active moderate to severe disease. Diagnosed with Systemic Lupus Erythematosus (SLE) at least 24 weeks before the screening visit. On at least one immunosuppressant and/or antimalarial for 12 weeks or more prior to the screening visit, must be at a stable dose for 8 weeks or more before the screening visit, and must remain stable until randomization and throughout study participation.If on an oral corticosteroid (prednisone or equivalent), the dose must be stable for 2 weeks or more before the screening visit, and cannot exceed 30 mg/day at screening, and must remain stable until the Week 4 visit.
